Dose intensity Sample Clauses

Dose intensity. Dose intensity of AZD5363 and paclitaxel will be addressed by considering relative dose intensity (RDI) defined as follows: RDI = 100% * d/D where d is the actual cumulative dose delivered up to the earlier of progression (or a censoring event) or the actual last day of dosing and D is the intended cumulative dose up to the earlier of progression (or a censoring event) or the actual last day of dosing plus the protocol-defined post-dose rest period. If there is no progression and a patient had no evaluable assessments then to calculate RDI for AZD5363, the patient will be censored at day 2 (i.e. the first day of AZD5363 dosing) and for calculating RDI for paclitaxel, the patient will be censored at day 1. RDI for AZD5363 and paclitaxel will be calculated for the entire intended treatment period.
Sample 1
AutoNDA by SimpleDocs
Dose intensity. Dose intensity of AZD5363 and paclitaxel will be addressed by considering relative dose intensity (RDI) and Percent intended dose (PID), defined as follows: RDI = 100% * d/D where d is the actual cumulative dose delivered up to the earlier of progression (or a censoring event) or the actual last day of dosing and D is the intended cumulative dose up to the earlier of progression (or a censoring event) or the actual last day of dosing plus the protocol-defined post-dose rest period. PID = 100% * d1/D1 Where d1 is the actual cumulative dose delivered up to progression (or a censoring event) and D1 is the intended cumulative dose up to progression (or a censoring event). D1 is the total dose that would be delivered, if there were no modifications to dose or schedule. RDI and PID for AZD5363 and paclitaxel will be calculated for the entire intended treatment period (censored at data cut-off).
Sample 1

Related to Dose intensity

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Community Based Adult Intensive Service (AIS) and Child and Family Intensive Treatment (CFIT) – AIS/CFIT programs offer services primarily based in the home and community for qualifying adults and children with moderate- to-severe mental health conditions. These programs consist at a minimum of ongoing emergency/crisis evaluations, psychiatric assessment, medication evaluation and management, case management, psychiatric nursing services, and individual, group, and family therapy. In a Provider’s Office/In Your Home This plan covers individual psychotherapy, group psychotherapy, and family therapy when rendered by: • Psychiatrists; • Licensed Clinical Psychologists; • Licensed Independent Clinical Social Workers; • Advance Practice Registered Nurses (Clinical Nurse Specialists/Nurse Practitioners- Behavioral Health); • Licensed Mental Health Counselors; and • Licensed Marriage and Family Therapists. Psychological Testing This plan covers psychological testing as a behavioral health benefit when rendered by: • neuropsychologists; • psychologists; or • pediatric neurodevelopmental specialists. This plan covers neuropsychological testing as described in the Tests, Labs and Imaging section.

  • Progression For progression for all classifications under this agreement, refer to Schedules A to D.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Population The Population shall be defined as all Paid Claims during the 12-month period covered by the Claims Review.

  • Rhytidectomy Scar revision, regardless of symptoms. • Sclerotherapy for spider veins. • Skin tag removal. • Subcutaneous injection of filling material. • Suction assisted Lipectomy. • Tattooing or tattoo removal except tattooing of the nipple/areola related to a mastectomy. • Treatment of vitiligo. • Standby services of an assistant surgeon or anesthesiologist. • Orthodontic services related to orthognathic surgery. • Cosmetic procedures when performed primarily: o to refine or reshape body structures or dental structures that are not functionally impaired; o to improve appearance or self-esteem; or o for other psychological, psychiatric or emotional reasons. • Drugs, biological products, hospital charges, pathology, radiology fees and charges for surgeons, assistant surgeons, attending physicians and any other incidental services, which are related to cosmetic surgery.

  • Progressive Payment For Property in which there is / are outstanding progressive payment(s) due to the Developer:-

  • Insulin Insulin will be treated as a prescription drug subject to a separate copay for each type prescribed.

  • Target Population The Grantee shall ensure that diversion programs and services provided under this grant are designed to serve juvenile offenders who are at risk of commitment to Department.

  • Influenza Vaccination The parties agree that influenza vaccinations may be beneficial for patients and employees. Upon a recommendation pertaining to a facility or a specifically designated area(s) thereof from the Medical Officer of Health or in compliance with applicable provincial legislation, the following rules will apply:

Time is Money Join Law Insider Premium to draft better contracts faster.